ACIU Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . AC Immune
ACIU Stock  USD 3.52  0.16  4.76%   
Analyzing historical trends in various income statement and balance sheet accounts from AC Immune's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AC Immune's valuation are summarized below:
Gross Profit
-57.2 M
Market Capitalization
338 M
Enterprise Value Revenue
37.483
Revenue
4.4 M
Earnings Share
(0.91)
There are currently one hundred twenty fundamental measures for AC Immune that can be evaluated and compared over time across peers in the sector. All traders should validate AC Immune's latest fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 476.2 M in 2026, whereas Market Cap is likely to drop slightly above 266.9 M in 2026.

AC Immune Total Revenue

20.1 Million

Check AC Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AC Immune's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 145.3 K or Selling General Administrative of 9.4 M, as well as many indicators such as Price To Sales Ratio of 9.77, Dividend Yield of 0.0 or PTB Ratio of 2.38. ACIU financial statements analysis is a perfect complement when working with AC Immune Valuation or Volatility modules.
  
Build AI portfolio with ACIU Stock
Check out the analysis of AC Immune Correlation against competitors.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

AC Immune Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets184 M265.5 M146.7 M
Slightly volatile
Other Current Liabilities117.3 M111.7 M26.2 M
Slightly volatile
Total Current Liabilities121.8 M116 M28.8 M
Slightly volatile
Total Stockholder Equity155.6 M129.1 M117.3 M
Slightly volatile
Other Liabilities5 M3.7 M3.7 M
Slightly volatile
Net Tangible Assets145.5 M136.4 M109.1 M
Slightly volatile
Property Plant And Equipment Net4.7 M9.3 M4 M
Slightly volatile
Accounts Payable1.9 M3.1 M1.8 M
Slightly volatile
Cash39.6 M41.7 M71.9 M
Pretty Stable
Non Current Assets Total71.1 M67.8 M23.4 M
Slightly volatile
Non Currrent Assets Other831.8 K477.3 K625.2 K
Pretty Stable
Other Assets234.4 K415.1 K220.5 K
Slightly volatile
Cash And Short Term Investments152 M190.3 M119.6 M
Slightly volatile
Net Receivables939.6 K989.1 K3.5 M
Very volatile
Common Stock Shares Outstanding73.9 M114.6 M65.7 M
Slightly volatile
Liabilities And Stockholders Equity183.9 M265.5 M146.5 M
Slightly volatile
Other Current Assets3.5 M6.2 M3 M
Slightly volatile
Other Stockholder Equity300.1 M550 M255.5 M
Slightly volatile
Total Liabilities143.3 M136.4 M36 M
Slightly volatile
Total Current Assets160.5 M197.8 M126.2 M
Slightly volatile
Common Stock1.6 M2.6 M1.4 M
Slightly volatile
Property Plant Equipment8.5 M8.1 M4.1 M
Slightly volatile
Current Deferred Revenue102.7 M97.8 M17.3 M
Slightly volatile
Common Stock Total Equity1.3 M1.8 M1.2 M
Slightly volatile
Non Current Liabilities Total21.5 M20.5 M7.7 M
Slightly volatile
Capital Surpluse235.2 M398.5 M234.3 M
Slightly volatile
Property Plant And Equipment Gross24.8 M23.6 M7.8 M
Slightly volatile
Net Invested Capital145.8 M101 M148.5 M
Slightly volatile
Net Working Capital127.5 M64 M135.6 M
Very volatile
Capital Stock1.9 M2.6 M1.6 M
Slightly volatile

AC Immune Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M2.5 M1.1 M
Slightly volatile
Selling General Administrative9.4 M13.1 M7.9 M
Slightly volatile
Total Revenue20.1 M24.6 M21.9 M
Very volatile
Other Operating Expenses58.5 M91.6 M49.9 M
Slightly volatile
Research Development46.1 M72 M39.6 M
Slightly volatile
Cost Of Revenue46.1 M72 M39.6 M
Slightly volatile
Total Operating Expenses36.1 M19.7 M26.9 M
Slightly volatile
Interest Income3.9 M3.7 M1.7 M
Slightly volatile
Reconciled Depreciation2 M2.5 M1.3 M
Slightly volatile

AC Immune Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.6 M6.3 M2.6 M
Slightly volatile
Begin Period Cash Flow100.1 M90.3 M79.2 M
Slightly volatile
Depreciation1.4 M2.5 M1.2 M
Slightly volatile
Capital Expenditures1.3 M662.4 K983.3 K
Slightly volatile
End Period Cash Flow39.6 M41.7 M71.9 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.7710.2936.3253
Slightly volatile
PTB Ratio2.382.538.4943
Slightly volatile
Days Sales Outstanding32.1733.86148
Slightly volatile
Book Value Per Share1.641.011.6231
Slightly volatile
Stock Based Compensation To Revenue0.160.180.2025
Slightly volatile
Capex To Depreciation0.290.311.046
Slightly volatile
PB Ratio2.382.538.4943
Slightly volatile
EV To Sales8.548.9931.7965
Slightly volatile
Payables Turnover41.8121.1943.0322
Pretty Stable
Sales General And Administrative To Revenue0.580.380.8219
Slightly volatile
Research And Ddevelopement To Revenue2.732.063.7382
Slightly volatile
Capex To Revenue0.0180.0190.0812
Pretty Stable
Cash Per Share1.611.491.6529
Slightly volatile
Days Payables Outstanding22.317.8321.3302
Slightly volatile
Intangibles To Total Assets0.190.20.2041
Slightly volatile
Current Ratio1.861.968.1584
Pretty Stable
Tangible Book Value Per Share0.530.561.3915
Pretty Stable
Receivables Turnover13.5414.2618.55
Very volatile
Shareholders Equity Per Share1.641.011.6177
Slightly volatile
Debt To Equity0.04570.04350.0141
Slightly volatile
Capex Per Share0.00490.00520.0139
Pretty Stable
Graham Net Net0.420.441.2857
Pretty Stable
Revenue Per Share0.470.320.3622
Very volatile
Interest Debt Per Share0.05270.05020.0246
Slightly volatile
Debt To Assets0.02220.02120.0093
Slightly volatile
Graham Number7.066.735.3597
Slightly volatile
Price Book Value Ratio2.382.538.4943
Slightly volatile
Days Of Payables Outstanding22.317.8321.3302
Slightly volatile
Ebt Per Ebit0.790.870.9693
Pretty Stable
Company Equity Multiplier1.532.371.7795
Slightly volatile
Long Term Debt To Capitalization0.00110.00120.0026
Slightly volatile
Total Debt To Capitalization0.04360.04150.0136
Slightly volatile
Debt Equity Ratio0.04570.04350.0141
Slightly volatile
Quick Ratio1.461.548.1049
Pretty Stable
Net Income Per E B T1.11.151.0167
Slightly volatile
Cash Ratio0.390.415.6104
Very volatile
Days Of Sales Outstanding32.1733.86148
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.141.0389
Slightly volatile
Price To Book Ratio2.382.538.4943
Slightly volatile
Fixed Asset Turnover3.693.8814.6058
Slightly volatile
Debt Ratio0.02220.02120.0093
Slightly volatile
Price Sales Ratio9.7710.2936.3253
Slightly volatile
Asset Turnover0.130.140.3226
Slightly volatile
Price Fair Value2.382.538.4943
Slightly volatile

AC Immune Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap266.9 M281 M501.6 M
Slightly volatile
Enterprise Value476.2 M245.5 M445.9 M
Slightly volatile

ACIU Fundamental Market Drivers

Forward Price Earnings11.236
Cash And Short Term Investments165.5 M

ACIU Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
26th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AC Immune Financial Statements

AC Immune shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although AC Immune investors may analyze each financial statement separately, they are all interrelated. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses on on AC Immune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue97.8 M102.7 M
Total Revenue24.6 M20.1 M
Cost Of Revenue72 M46.1 M
Stock Based Compensation To Revenue 0.18  0.16 
Sales General And Administrative To Revenue 0.38  0.58 
Research And Ddevelopement To Revenue 2.06  2.73 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.32  0.47 
Ebit Per Revenue(2.21)(2.32)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY